No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Uromedica Announces the Initiation of its FDA Investigational Device Exemption Trial for ACT® to Evaluate its Safety and Efficacy for RX of SUI

Editor: What To Know

  • The ACT protocol is a non-randomized trial expected to enroll up to 167 subjects with 12-month follow-up in which provocative pad weight test will be the primary clinical endpoint.
  • Uromedica notes the investigational intent of the ACT trial, a post-operatively adjustable, minimally invasive outpatient procedure, is to assess safety and efficacy for women who suffer from moderate or severe SUI.
  • , urologist and Chairman of the Urology Department at Creighton University in Omaha, Nebraska, performed the first ACT implantations in early February 2021.

March 10, 2021

Uromedica notes the investigational intent of the ACT trial, a post-operatively adjustable, minimally invasive outpatient procedure, is to assess safety and efficacy for women who suffer from moderate or severe SUI.

The ACT protocol is a non-randomized trial expected to enroll up to 167 subjects with 12-month follow-up in which provocative pad weight test will be the primary clinical endpoint. FDA has permitted up to 11 sites in the U.S. to enroll patients. To learn more about the ACT study click here.

Michael Feloney, M.D., urologist and Chairman of the Urology Department at Creighton University in Omaha, Nebraska, performed the first ACT implantations in early February 2021. Dr. Feloney stated: “ACT offers a unique approach to the management of female stress urinary incontinence. It is exciting to be participating in this FDA trial at Creighton University Medical Center. I am confident that ACT will be similar to ProACT in providing relief for my patients suffering from stress urinary incontinence.” ProACT™, Adjustable Continence Therapy for Men, was FDA-approved in 2015 for the treatment of SUI in men after prostate surgery.

Timothy Cook, Ph.D., President and CEO of Uromedica commented: “Uromedica is very pleased to have begun our ACT trial. We are fortunate to be working with highly trained and skilled surgeons in a number of premier academic Urologic and Urogynecologic practices.“

Adjustable Continence Therapy for Women: Designed to be adjustable after implantation without further surgery, the ACT consists of two small silicone balloons connected with tubing to a filling port. The balloons are surgically placed next to the bladder and the ports are placed underneath the skin for later access and adjustment. The fluid-filled balloons provide support at the bladder neck, protecting against accidental urine leakage.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy